A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Fragile X Syndrome
Interventions
DRUG

zatolmilast

Subjects will receive a 15 mg or 25 mg dose of zatolmilast (BPN14770) or placebo

DRUG

Placebo

Placebo

Trial Locations (17)

10029

Icahn School of Medicine at Mount Sinai Hospital, New York

17579

Clinic for Special Children, Strasburg

19063

Suburban Research Associates, Media

21205

Kennedy Krieger Institute, Baltimore

29605

Greenwood Genetic Center, Greenville

30322

Emory University School of Medicine, Atlanta

33136

University of Miami, Miami

45229

Cincinatti Children's Hospital Medical Center, Cincinnati

60612

Rush University Medical Center, Chicago

66160

University of Kansas Medical Center, Kansas City

80045

Children's Hospital Colorado, Aurora

84113

University of Utah and Primary Childrens Hospital, Salt Lake City

92604

Amnova Clinical Research, Irvine

92868

Thompson Autism & Neurodevelopment Center - CHOC, Orange

95817

UC Davis, Sacramento

02115

Boston Children's Hospital, Boston

01655

U Mass, Worcester

Sponsors
All Listed Sponsors
lead

Tetra Discovery Partners

INDUSTRY

NCT05163808 - A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome | Biotech Hunter | Biotech Hunter